Predictive Oncology (NASDAQ: POAI) has entered the
race to develop a COVID-19 vaccine with the announced acquisition of Soluble
Therapeutics, Inc. and the subsequent partnership and licensing of a novel
nanoparticle vaccine platform recently developed by Dr. Daniel Carter.
According to the update, the groundbreaking vaccine technology being developed
by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is
Non Specific Protein), which follows a foundational vaccine platform developed
earlier by Dr. Carter and his team, using another self-assembling protein
called ferritin (1), an iron storage protein found in all living things. NIH is
currently exploiting the ferritin platform in its exploration of the universal
flu vaccine which completed phase I clinical trials earlier this year and is
currently recruiting for a second phase 1 trial on a modified version of the
ferritin self-assembly universal vaccine (2,3). POAI has entered into an
agreement with Dr. Carter under which it is licensing this technology, subject
to certain conditions. According to Dr. Carter, principal inventor of the
ferritin self-assembling nanoparticle platform (1), now widely applied by many,
including NIH, to other applications and principal inventor of the new NSP10
approach, “NSP10 is a ‘game changer’ vaccine platform with significant
advantages. These game changer properties have also been validated with
SARS-CoV-2 vaccine candidates – resulting in extraordinary animal titers
against the coronavirus spike protein which is required for viral infectivity –
all with a simple injection of small quantities of DNA.”
To view the full press release, visit http://ibn.fm/mnDtT
About Predictive Oncology Inc.
Predictive Oncology operates through three segments
(domestic, international and other) that contain four subsidiaries; Helomics,
TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial
intelligence to its rich data gathered from patient tumors to both personalize
cancer therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists oncologists in
individualizing patient treatment decisions, by providing an evidence-based
road map for therapy. In addition to its proprietary precision oncology
platform, Helomics offers boutique CRO services that leverage its TruTumor(TM),
patient-derived tumor models coupled with a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform to provide a tailored solution to its clients’ specific
needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid
approach to growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform Kits will assist researchers and
clinicians to identify which cancer cells bind to specific biomarkers. Once the
biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture
Technology Platforms, which isolate and help categorize an individual patient’s
heterogeneous tumor samples to enable the development of patient-specific
treatment options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented and
FDA-cleared STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and others, within a
medical facility, through both domestic and international divisions. The
company has achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, visit the company’s
website at www.Predictive-Oncology.com.
1. C. Carter and C. Li, “Genetically Engineered Ferritin
as a Vehicle for Vaccine Production, Biomaterials, Oxygen Transport, and
Therapeutic Delivery, issued in Germany, France, United Kingdom, China and
Canada, US Patent No. 7,097,841(2006)
2. Influenza HA Ferritin Vaccine, Alone or in Prime-Boost
Regimens with an Influenza DNA Vaccine in Healthy Adults: http://nnw.fm/YQ15a
3. Dose, Safety, Tolerability and Immunogenicity of an
Influenza H1 Stabilized Stem Ferritin Vaccine, VRCFLUNPF099-00-VP, in Healthy
Adults: http://nnw.fm/ecA41
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
